NCT07548957尚未招募1 期
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- AUCt
研究概览
简要总结
This study was an open-label, randomized, single-dose, 2-sequence, 2-period, crossover study to evaluate the safety and pharmacokinetics of UI087 compared to coadministration of UIC202506, UIC202507 and UIC202508 in healthy adult volunteers under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged 19 years or older at the screening visit
- •Subjects with a body weight ≥ 50 kg (≥ 45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg/m² at the screening visit
- •BMI (kg/m²) = body weight (kg) / {height (m)}²
- •Subjects without clinically significant congenital or chronic diseases and without pathological symptoms or findings based on medical examination at the screening visit
- •Subjects deemed eligible for participation based on diagnostic tests (hematology, blood chemistry, serology, urinalysis, etc.) and ECG, as determined by the investigator (or delegated sub-investigator) according to the characteristics of the investigational product
- •Subjects who agree to use medically acceptable contraception* (excluding hormonal methods) from the first dose until 7 weeks after the last dose of the investigational product, to prevent pregnancy for themselves or their spouse/partner, and who agree not to donate sperm or ova
- •Medically acceptable contraception: Use of intrauterine devices, vasectomy, tubal ligation, and/or barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.), or the use of spermicide in combination with at least two barrier methods
- •Subjects who voluntarily sign the informed consent form after receiving and fully understanding sufficient explanation regarding the purpose, procedures, characteristics of the investigational product, and expected adverse events of the clinical trial
排除标准
- •Subjects with clinically significant diseases or a history of diseases involving the gastrointestinal, cardiovascular, endocrine, respiratory, hematologic/oncologic, infectious, renal and genitourinary, psychiatric/neurological, musculoskeletal, immune, ENT, dermatologic, or ophthalmologic systems
- •Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) that may affect drug absorption, or with gastrointestinal diseases
- •Subjects who have taken enzyme-inducing or inhibiting drugs (e.g., barbiturates) within 1 month prior to the first dose, or medications that may affect the clinical trial within 10 days prior to the first dose (Participation may be allowed depending on pharmacokinetic/pharmacodynamic properties such as interactions and half- life)
- •Subjects who have participated in another clinical trial or bioequivalence study and received an investigational product within 6 months prior to the first dose
- •Subjects who have donated whole blood within 8 weeks, donated blood components within 2 weeks, or received a transfusion within 4 weeks prior to the first dose
- •Subjects meeting the following conditions within 1 month prior to the first dose:
- •Alcohol consumption exceeding an average of 21 drinks/week for males
- •Alcohol consumption exceeding an average of 14 drinks/week for females
- •(1 drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer)
- •Smoking more than an average of 20 cigarettes per day
- •Subjects who meet the following:
- •Hypersensitivity to the active ingredient, excipients of the investigational product, or a drug in the same class as the investigational product
- •Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •Subjects with the following conditions:
- •Type 1 diabetes mellitus, lactic acidosis, or acute/chronic metabolic acidosis including diabetic ketoacidosis (with or without coma), or a history of ketoacidosis
- •Moderate (stage 3b) or severe renal impairment (GFR < 45 mL/min/1.73 m²), or acute conditions that may affect renal function such as dehydration, severe infection, cardiovascular collapse (shock), acute myocardial infarction, or sepsis
- •Acute or unstable heart failure
- •Patients undergoing intravascular iodinated contrast imaging (e.g., intravenous urography, cholangiography, angiography, contrast-enhanced CT, etc.)
- •Diabetic pre-coma
- •Severe infections or severe traumatic systemic disorders
- •Patients scheduled for surgery
- •Patients with malnutrition, starvation, debility, hypopituitarism, or adrenal insufficiency
- •Patients with acute or chronic conditions that may cause tissue hypoxia (e.g., hepatic impairment, respiratory failure, acute myocardial infarction, shock)
- •Patients with excessive alcohol intake or gastrointestinal disorders such as dehydration, diarrhea, or vomiting
- •Subjects deemed unsuitable for participation by the investigator (or delegated sub-investigator) for any other reason not specified above
- •Female subjects who are pregnant, suspected to be pregnant, or breastfeeding
研究组 & 干预措施
UI087
Experimental
Test
干预措施: Administration of UI087 (Drug)
UIC202506, UIC202507, UIC202508
Active Comparator
Reference
干预措施: Administration of UIC202506, UIC202507, UIC202508 (Drug)
结局指标
主要结局
AUCt
时间窗: 0 to 72 hours
Evaluation PK after single dose
Cmax
时间窗: 0 to 72 hours
Evaluation PK after single dose
次要结局
- AUC∞(0 to 72 hours)
- Tmax(0 to 72 hours)
- t1/2(0 to 72 hours)
- λz(0 to 72 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of WP205 in Healthy ParticipantsNCT07281872Wanbangde Pharmaceutical Group Co., LTD20
已完成
1 期
A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in ChinaNCT07300436TJ Biopharma Co., Ltd.96
已完成
不适用
Study to investigate Bioavailability of Fexofenadine Hydrochloride 30 mg and 60 mg Chewable Tablet in healthy adult human participants.CTRI/2025/10/095585Opella Healthcare Group SAS20
已完成
2/3 期
A study to evaluate the blood levels of Brivaracetam SR Tablets 200 mg to measure the pharmacokinetic profiles, safety and tolerability of the Test product (of Optimus Pharma Pvt. Ltd.) when compared to the reference product (BRITZILAM SR Tablets 200 mg) in a healthy subject in a fasting condition.CTRI/2024/02/062873Optimus Pharma Pvt Ltd24
尚未招募
不适用
A study comparing how well the body absorbs two different formulations of Curcuma longa (Turmeric) extract in healthy adults under (fasting conditions).CTRI/2025/04/084854Chemiloids Life Sciences Private Limited.16